THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q3 2017 13F Holders as of 30 Sep 2017

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
97.58%
Total 13F principal
$203,018,692
Principal change
-$36,407,308
Total reported market value
$198,273,884
Number of holders
29
Value change
-$31,617,856
Number of buys
15
Number of sells
17

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q3 2017

As of 30 Sep 2017, THERAVANCE INC - CORPORATE OBLIG was held by 29 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $203,018,692 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, CNH PARTNERS LLC, OAKTREE CAPITAL MANAGEMENT LP, Calamos Advisors LLC, LAZARD ASSET MANAGEMENT LLC, AMUNDI PIONEER ASSET MANAGEMENT INC, DEUTSCHE BANK AG\, Castle Creek Arbitrage, LLC, AMERIPRISE FINANCIAL INC, and SSI INVESTMENT MANAGEMENT INC. This page lists 29 institutional bondholders reporting positions for the Q3 2017 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.